EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

Ryoichi Miura, Atsushi Ono iD, Hikaru Nakahara, Yuki Shirane, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge und 6 weitere

Journal of Gastroenterology · 2025

DOI: 10.1007/s00535-024-02185-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Ryoichi Miura und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, 734-8551, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Interleukin-6, Bevacizumab. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science London, Takeda Foundation, Bristol Myers Squibb Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aims to identify biomarkers for treatment response of atezolizumab plus bevacizumab (Atezo+Bev) in patients with hepatocellular carcinoma (HCC).

Methods

96 patients who received Atezo+Bev or lenvatinib as a first-line systemic therapy were enrolled as the training group after propensity score matching (PSM), and 42 patients treated with Atezo+Bev were enrolled as the validation group. 17 serum cytokines were measured by Luminex multiplex assay at the start of treatment. For further assessment of the association between cytokine levels and the tumor microenvironment (TME), immunohistochemistry (IHC) was performed on pre-treatment liver biopsy specimens.

Results

In the derivation set, multivariate analysis identified elevated IL-6 as an independent risk factor in the Atezo+Bev group (HR 5.80: p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsInterleukin-6BevacizumabAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAntibodies, Monoclonal, HumanizedMiddle AgedBiomarkers, TumorAgedQuinolinesTumor MicroenvironmentPhenylurea CompoundsTreatment OutcomePrognosis

Stichwörter der Autor:innen

Atezolizumab plus bevacizumabInterleukin-6Unresectable hepatocellular carcinoma

Substanzen

atezolizumabInterleukin-6Antibodies, Monoclonal, HumanizedBevacizumabBiomarkers, TumorlenvatinibQuinolinesIL6 protein, humanPhenylurea Compounds

Autor:innen und Institutionen

  • Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, 734-8551, Japan.
  • Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hospital, Hiroshima, 734-8551, Japan. atsushi-o@hiroshima-u.ac.jp.
  • Department of Clinical Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Liver Center, Hiroshima University, Hiroshima, 734-8551, Japan.
  • Biosample Research Center, Radiation Effects Research Foundation, Hiroshima, Japan.
  • Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan.

ORCID-Profile: Atsushi Ono

Förderung

  • Japan Society for the Promotion of Science London
  • Takeda Foundation
  • Bristol Myers Squibb Foundation
  • Hiroshima University

Zitieren

APA

Miura, R., Ono, A., Nakahara, H., Shirane, Y., Yamaoka, K., Fujii, Y., Uchikawa, S., Fujino, H., Murakami, E., Kawaoka, T., Miki, D., Tsuge, M., Kishi, T., Ohishi, W., Sakamoto, N., Arihiro, K., Hayes, C. N., & Oka, S. (2025). Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02185-w

Vancouver

Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, et al. Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. Journal of Gastroenterology. 2025. doi:10.1007/s00535-024-02185-w

BibTeX
@article{Miura2025,
  author = {Miura, Ryoichi and Ono, Atsushi and Nakahara, Hikaru and Shirane, Yuki and Yamaoka, Kenji and Fujii, Yasutoshi and Uchikawa, Shinsuke and Fujino, Hatsue and Murakami, Eisuke and Kawaoka, Tomokazu and Miki, Daiki and Tsuge, Masataka and Kishi, Takeshi and Ohishi, Waka and Sakamoto, Naoya and Arihiro, Koji and Hayes, Clair Nelson and Oka, Shiro},
  title = {Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma},
  journal = {Journal of Gastroenterology},
  year = {2025},
  doi = {10.1007/s00535-024-02185-w}
}
Kostenlos starten →